May 6 (Reuters) – Bayer said on Wednesday new analyses showed its experimental blood thinner asundexian reduced the incidence and severity of ischaemic strokes.
Data from a phase III trial showed fewer ischaemic strokes occurred with the drug (6.2%) compared with placebo (8.4%) in patients who have suffered a non-cardioembolic ischaemic stroke or a high-risk transient ischaemic attack.
(Reporting by Patricia Weiss, writing by Linda Pasquini, editing by Kirsti Knolle)
